Basics NovoCure Limited Ordinary Shares NovoCure Ltd is a medical systems developer in the United States. Its primary product is the TTFields delivery system, which is a low-intensity therapy to combat acute tumors. IPO Date: September 28, 2015 Sector: Healthcare Industry: Medical Instruments and Supplies Market Cap: $1.37B Activated in VL: True Average Daily Range Avg Daily Range: $1.32 | 2.70% Avg Daily Range (30 D): $0.35 | 2.62% Avg Daily Range (90 D): $0.39 | 2.42% Institutional Daily Volume Avg Daily Volume: .78M Avg Daily Volume (30 D): 1.67M Avg Daily Volume (90 D): 1.23M Trade Size Avg Trade Size (Sh.): 72 Avg Trade Size (Sh.) (30 D): 80 Avg Trade Size (Sh.) (90 D): 70 Institutional Trades Total Inst.Trades: 4,998 Avg Inst. Trade: $3.6M Avg Inst. Trade (30 D): $1.84M Avg Inst. Trade (90 D): $2.43M Avg Inst. Trade Volume: .07M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $5.52M Avg Closing Trade (30 D): $2.34M Avg Closing Trade (90 D): $2.73M Avg Closing Volume: 107.07K     News Aug 29, 2025 @ 8:26 AM 2 Beaten-Down Stocks That Could Rocket 142% to 222... Source: Cory Renauer Jul 24, 2025 @ 1:21 PM Novocure: Steady Ahead of Key Milestones Source: Lou Whiteman Apr 24, 2025 @ 1:25 PM NovoCure Surpasses Q1 Expectations Source: Jesterai Apr 16, 2025 @ 7:43 PM Why NovoCure Stock Was Withering on Wednesday Source: Eric Volkman Dec 6, 2024 @ 1:32 PM Why NovoCure Stock Was Winning Big This Week Source: Eric Volkman Financials   TTM Q2 2025 Q1 2025 Basic EPS $-1.56 $-.36 $-.31 Diluted EPS $-1.56 $-.36 $-.31 Revenue $ 630.16M $ 158.81M $ 154.99M Gross Profit $ 481.33M $ 117.33M $ 116.47M Net Income / Loss $ -170.95M $ -40.14M $ -34.32M Operating Income / Loss $ -172.78M $ -39.52M $ -37.87M Cost of Revenue $ 148.83M $ 41.47M $ 38.52M Net Cash Flow $ -16.31M $ 22.7M $ -36.66M PE Ratio